Lilly's ED drug gets daily dose

Eli Lilly's tadalafil was the little blue pill's lesser sibling at first, but it's gained momentum, especially outside the U.S. With a low-dose pill approved yesterday by the FDA, is may just pull ahead domestically, too.

Taken daily, the low-dose version allows men to attempt sexual activity anytime. Previously, men had to take tadalafil ahead of time; it remained effective for 36 hours. Other treatments work for about four hours.

Lilly hopes that this new, more convenient dosing helps sales continue to grow: For the first nine months of 2007, the drug brought in $798 million, and the company expects it to top $1 billion for the full year. The nine-months results are 30 percent higher than same-period-last-year sales.

- here's Lilly's release
- read the article from the Indianapolis Star

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.